Patient Rating:

No Rating Available?

Adam M. Spivak, M.D.

Specialties

Languages

  • English

Clinical Details

Locations

Schedule An Appointment Clinical Office Address
(801) 585-2031 University Hospital
Infectious Diseases, Clinic 1A
50 N Medical Dr
Salt Lake City, UT 84132
Map

Bio

Dr. Spivak joined the Division of Infectious Diseases as a Visiting Instructor in the fall of 2011. He cares for HIV patients as a member of the Clinic 1A staff at the University of Utah Hospital and attends on the inpatient Infectious Diseases consult service at both the University and VA Hospitals.

Board Certification and Academic Information

Academic Departments Internal Medicine - Visiting Instructor
Academic Divisions Infectious Diseases
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Infec Disease)

Academic Profile

Board Certification and Academic Information

Academic Departments Internal Medicine - Visiting Instructor
Academic Divisions Infectious Diseases
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Infec Disease)

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 581-8812 School of Medicine
Infectious Diseases
30 N Medical Dr
Salt Lake City, UT 84132

Academic Bio

Dr. Spivak joined the Division of Infectious Diseases in October 2011 after completing Infectious Diseases fellowship training at Johns Hopkins University School of Medicine. His primary focus is on translational research exploring HIV persistence and strategies for viral eradication.

During fellowship, Dr. Spivak spent three years in the laboratory of Dr. Robert Siliciano where he studied cellular reservoirs of HIV and helped to run a pilot clinical trial of a novel HIV eradication strategy. In May 2011, Dr. Spivak was awarded a Bill and Melinda Gates Foundation Grand Challenges Explorations Grant for a research proposal describing an in vitro screening assay to identify compounds able to selectively induce apoptosis in HIV infected cells.

At the University of Utah, Dr. Spivak will spend the majority of his time in the laboratory of Vicente Planelles in the Department of Pathology. Working with members of the Planelles lab, he will continue his ongoing research into the nature of HIV persistence. He cares for HIV patients as a member of the Clinic 1A staff at the University of Utah Hospital and attends on the inpatient Infectious Diseases consult service at both the University and VA Hospitals.

Education

Education History

Type School Degree
Fellowship Johns Hopkins University School of Medicine
Infectious Diseases
Fellow
Chief Resident Johns Hopkins University School of Medicine
Internal Medicine
Chief Resident
Residency Johns Hopkins University School of Medicine
Internal Medicine
Resident
Internship Johns Hopkins University School of Medicine
Internal Medicine
Intern
Professional Medical University of Maryland School of Medicine
Medicine
M.D.
Undergraduate Princeton University
English Literature
A.B.

Publications

Selected Provider Publications

Journal Article

  1. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks S(2014)A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy.  Clinical Infectious Diseases,
  2. Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA, Spivak AM, Siliciano RF, Stivers J(2013)Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration.  Proceedings of the National Academy of Sciences of the United States of America, 110(6),E448-57
  3. Barber AE, Norton JP, Spivak AM, Mulvey M(2013)Urinary Tract Infections: Current and Emerging Management Strategies.  Clinical Infectious Diseases,
  4. Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, Siliciano R(2011)Short Communication: Dynamic Constraints on the Second Phase Compartment of HIV-Infected Cells.  AIDS Research and Human Retroviruses, 27(7),759-61
  5. Gaillard S, Dinoso JB, Marsh JA, Dezern AE, O'Connell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson J(2011)Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy.  Journal of Clinical Virology, 51(3),195-8
  6. Spivak AM, Salgado M, Rabi SA, O'Connell KA, Blankson J(2011)Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors.  Journal of Virology, 85(19),10399-403
  7. Spivak AM, Brennan TP, O'Connell KA, Sydnor E, Williams TM, Siliciano RF, Gallant JE, Blankson J(2010)A case of seronegative HIV-1 infection.  Journal of Infectious Diseases, 201(3),341-5

Review

  1. Spivak AM, Sydnor ER, Blankson JN, Gallant J(2010)Seronegative HIV-1 infection: a review of the literature.  AIDS, 24(10),1407-14
  2. Pradilla G, Nagahama Y, Spivak AM, Bydon A, Rigamonti (2010)Spinal epidural abscess: current diagnosis and management.  Current Infectious Disease Reports, 12(6),484-91

Letter

  1. Spivak AM, Siliciano R(2010)Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk.  AIDS, 24(10),1603-404; author reply 1604

Poster

  1. Spivak AM, Andrade A, Hoh R, Bacchetti P, Eisele E, Buckheit III R, Lai J, Siliciano J, Siliciano R, Deeks (2012)Safety and Feasibility of Using Disulfiram to Enhance HIV Transcription among Long-term ARV-treated Adults: Preliminary Results from a Pilot Study  ,
  2. Spivak AM, Gaillard S, Dinoso J, Marsh J, Blankson (2011)Sustained Elite Suppression of Replication Competent HIV-1 in a Patient Treated with Rituximab Based Chemotherapy. [Abstract 291]  ,
  3. Spivak AM, Reza A, McMahon M, Sedaghat A, Siliciano R(2009)Understanding Decay of Viremia in Patients on Raltegravir. . [Abstract 552]  ,

Clinical Trials

Video & News